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Editor’s key points
† This study determines
compartmental
pharmacokinetic
parameters for nefopam
during hypothermia.
† The plasma
concentration time
course best fitted a
two-compartment model
using a population
approach with
inter-occasional
variability.
† No statistically significant
covariates were found.
† This model can be used
to optimize nefopam
administration by
target-controlled
infusion.
Background. Nefopam is a non-opioid, non-steroidal, centrally acting analgesic which
has an opioid-sparing effect. It also reduces the threshold (triggering core
temperature) for shivering without causing sedation or respiratory depression. The drug
is therefore useful as both an analgesic and to facilitate induction of therapeutic
hypothermia. However, compartmental pharmacokinetics during hypothermia are lacking
for nefopam.
Methods. We conducted a prospective, randomized, blinded study in eight volunteers. On
two different occasions, one of two nefopam concentrations was administered and more
than 30 arterial blood samples were gathered during 12 h. Plasma concentrations were
determined using gas chromatography/mass spectrometry to investigate the
pharmacokinetics of nefopam with non-linear mixed-effect modelling.
Results. A two-compartment mammillary model with moderate inter-individual variability
and inter-occasional variability independent of covariates was found to best describe the
data [mean (SE): V1¼24.13 (2.8) litre; V2¼183.34 (13.5) litre; Clel¼0.54 (0.07) litre min21;
Cldist¼2.84 (0.42) litre min21].
Conclusions. The compartmental data set describing a two-compartment model was
determined and could be implemented to drive automated pumps. Thus, work load could
be distributed to a pump establishing and maintaining any desired plasma concentration
deemed necessary for a treatment with therapeutical hypothermia.
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Mild hypothermia in animals provides substantial protection
against cerebral1 2 and myocardial ischaemia3 and in
humans, mild hypothermia (33–348C) improves long-term
neurological and functional outcome after cardiac arrest.4 5
Therapeutic hypothermia also improves outcome from
neonatal asphyxia.6 7 A difficulty with therapeutic hypo-
thermia, though, is that even small reductions in core tempera-
ture trigger aggressive thermoregulatory defences,8 9
especially arterio-venous shunt vasoconstriction10 and shi-
vering.11 This has led to a search for drugs that impair vaso-
constriction and shivering without causing excessive
sedation or respiratory toxicity.12
Among the potential pharmacological approaches to indu-
cing hypothermic tolerance is nefopam. Nefopam is a non-
opioid, non-steroidal analgesic with spinal and supraspinal
sites of action that selectively reduces the shivering threshold
(triggering core temperature) without impairing respiration or
conciousness.13–19 It is a benzoxazocine compound, structur-
ally related to orphenadrine and diphenhydramine, that inhi-
bits the reuptake of serotonin, norepinephrine, and
dopamine20 in an amphetamine-like fashion.18 Nefopam
reduces the shivering threshold and can thus facilitate the
induction of therapeutic hypothermia.21
Although limited pharmacological data are available,22
full compartmental models for nefopam during hypothermia
were not readily available. Thus, the goal of this study was to
determine compartmental pharmacokinetic (PK) parameters
for nefopam during hypothermia.
Methods
Data presented in this report were obtained during a previous
study that evaluated the thermoregulatory effects of
nefopam.23 Briefly, with approval of the local Institutional
Ethics Committee and informed patient consent, we
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evaluated eight young, healthy volunteers who took no med-
ications and denied alcohol or drug abuse. After nefopam
administration, lactated Ringer’s solution at 48C was
infused to provoke shivering which was the primary
outcome of the primary thermoregulatory protocol. The
maximum reduction in core temperature was .1.58C.
Throughout the study, volunteers rested supine.
A 14 G catheter was inserted into one antecubital vein for
fluid administration and a 16 G catheter into the other for
drug administration. Blood samples were drawn from a 20
G catheter inserted into a radial artery on the upper
extremity. On two different occasions, with a washout time
of more than 48 h, nefopam (Acupan, Laboratoires Biocodex,
Montrouge, France; IUPAC name: 5-methyl-1-phenyl-1,3,4,
6-tetrahydro-2,5-benzoxazocine) was administered as a
continuous i.v. infusion at two randomly assigned concentra-
tions (0.5 mg ml21 or 1.0 mg ml21) according to one of the
schemes displayed in the Appendix (volunteers 1–4,
scheme A; volunteers 5–8, scheme B).
Arterial blood was sampled for PK analysis according to the
following scheme: a blank sample; during nefopam administra-
tion at minutes 2, 4, 6, 8, 10, 12, 15, 20, 30, 45, and 60, and
immediately before stopping the nefopam infusion; if applic-
able, depending on the pharmacodynamic study part,
additionally at minutes 120, 150, and 180. The number of
samples during nefopam administration depended on the
duration of the thermoregulatory study. After stopping the
nefopam infusion, samples were gathered at minutes 2, 4, 6,
10, 15, 20, 30, 45, 60, 90, 120, 180, 275, 360, 450, 540, and 630.
Plasma was extracted in a refrigerated centrifuge and
stored at 2208C until assayed. Before extraction, plasma
samples for nefopam analysis were allowed to thaw at
room temperature and vortexed, then centrifuged at 2000
rpm for 5 min. To 0.5 ml of plasma, 0.5 ml of deionized
water, internal standard (IS, imipramine hydrochloride, ICN
Biomedicals Inc., OH, USA), and 30 ml of orthophosphoric
acid were added and vortexed. The samples were loaded
(about 0.5 ml min21) on 96-well solid phase extraction
plates with 2 ml capacity and 30 mg extraction bed (OASIS,
MCX, Waters Corporation, Milford, PA, USA). The cartridges
were rinsed with 2 ml of 0.1 M hydrochloric acid, 2 ml of
methanol, and then dried under vacuum for at least 5 min.
The extracts were then eluted from the cartridge with 2.5
ml of freshly prepared methanol–ammonium hydroxide 25%
(95:5; vol:vol), by gravity flow. The eluate was evaporated to
dryness under a nitrogen stream in a water bath at about
408C. The residues were redissolved in 30 ml methanol–
butylacetate (4:1; vol:vol), briefly vortexed, and loaded into
auto-sampler vials with inserts. Samples were analysed by
GC–MSD (Agilent Technologies, USA, Model 6890 with a
5972A mass selective detector and automatic injector).
Aliquots of 1 ml were injected in a splitless mode onto a
Varian FactorFour VF-Xms, 12 m, 0.2 mm ID capillary
column with a 0.33 mm film. The helium flow rate was 0.8
ml min21. Operating temperatures of the GC were: injector
2508C, MSD transfer line 2808C, oven 1408C for 0.2 min
rising (258C min21) to 2808C, hold 1 min. The MSD was
operated in the electron impact mode (70 eV) with selected
ion monitoring (SIM) with a dwell time of 100 ms each. SIM
ions for quantitation were m/z 225 and 235 for nefopam
and IS, respectively. The data were processed with propri-
etary mass spectrometer control software (HP G1701AA).
All calibration curves had correlation coefficients ≥0.99.
The coefficient of variation (CV) of intraday reproducibility
(n¼10) for nefopam at 301, 103, and 10.3 ng ml21 blood
content was 2.0%, 2.2%, and 3.7%, respectively. CV of inter-
day reproducibility at the same concentrations (n¼6) was
4.5%, 5.3%, and 7.4%, respectively. The mean recovery of
nefopam (n¼15) at concentrations 10–300 ng ml21 was
92.5% (range 87–104%). The limit of quantification at a
signal-to-noise ratio of 10:1 was 4.4 ng ml21. The limit of
detection at a signal-to-noise ratio of 3:1 was 1.3 ng ml21.
One-, two-, and three-compartment mammillary models
were fitted to the nefopam plasma concentration data and
compared using the Akaike information criterion.24 The
models were parameterized in terms of volumes of distribu-
tion, elimination, and distributional clearance (Clel, Cldist).
Pooled data were initially used, which means that each
data set was handled as if it was a single subject. In a
second step, we specified that the same subject participated
on two different occasions. Investigations were done with
a non-population and a population approach. In a third
step, intra-occasional variability (IOV) was taken into
consideration.
Inter-individual variability (IIV) was characterized by an
exponential model: u(n,i)¼u(n,m)×eh(n,i), where u(n,i) refers to
the individual value of the respective PK parameter, u(n,m)
the population mean of the parameter, and h(n,i) denotes
the ln-difference between u(n,i) and u(n,m). IIV is the square
root of the variances of the ETAs and is expressed as
percentage value. The IOV, the variability within one indi-
vidual between study occasions, had the same exponential
structure: u(n,iq)¼u(n,m)×eh(n,i)+k(n,iq), where q denotes the
occasion and k(n,iq) the additional random effect differing
from the typical individual value. h(n,i) and k(n,iq) are
assumed to vary randomly between individuals with a
mean of zero and a diagonal variance–covariance matrix
v2 and p2, respectively.
Residual variability denotes the discrepancy between the
observed and the model-predicted concentrations already
containing the IIV and IOV. A multiplicative error model
was chosen: cobs¼cexp(1+e), where cobs refers to the
observed concentration and cexp to the concentration pre-
dicted based on dose, time, and the individual PK para-
meters. e was assumed to be normally distributed with a
mean of zero and variance s2.
Covariates were age, weight, height, BMI, lean body mass
(LBM), and body surface area (BSA). The parameters were
plotted against these covariates for visual inspection. Covari-
ates were added one by one and kept in the model if they
improved the goodness of fit (forward inclusion, backward
deletion), judged by the likelihood ratio criterion (P≤0.01).
We tested for model misspecification by plotting the ratio
of the measured and the predicted nefopam plasma
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concentrations against observation time. Additionally, the
predictive performance of the final model was determined
applying prediction error (PE) analysis.25
PE=100(measured concentration−predicted concentration)
predicted concentration
The median PE (MDPE) indicates the bias of the predicted
concentration to the measured one and the absolute value
of PE called the median absolute PE (MDAPE) characterizing
the precision of the prediction. The model is most accurate
the closer the value of MDPE and MDAPE is to 0. Typical
accepted values during target-controlled infusion (TCI) are
ranging between 220% and 20% for the MDPE and ,30%
for the MDAPE.26 For all calculations, NONMEM version VII
with the first-order conditional estimation for all model fits
and empirical Bayesian estimation of the individual para-
meters was used.27 The bootstrap was performed using
Perl speaks NONMEM (Version 3.2.12; http://psn.sourceforge.
net), with a total of 2000 bootstrap samples being generated
by repeated random sampling from the original data set
preserving the two occasions per individual. Boundaries for
the elimination clearance were 0 and 100 litre min21.
Context-sensitive decrement times for the plasma concen-
tration were calculated using RECOV.C targeting times to
80%, 50%, and 20% decrements.
Results
If not otherwise indicated, the values are presented as mean
(SD) (min–max): age 28 (7) (21–39) yr, weight 78 (9) (63–92)
kg, and height 179 (4.7) (170–185) cm. Two of the eight
volunteers were female. Five hundred blood samples (249
from scheme A and 251 from scheme B) were available for
PK calculations, including the blank samples obtained
before drug administration. A total of 3.04 (0.78) litre
lactated Ringer’s solution at 48C were administered on the
low-concentration day (0.5 mg ml21 nefopam) and a total
of 3.43 (1.01) litre were used on the high-concentration day
(1.0 mg ml21 nefopam).
Raw plots of the measured nefopam plasma concentra-
tion were constructed for infusion schemes A and B, and
showed a typical initial peak followed by a decrease in the
nefopam plasma concentration reaching a plateau until
maintenance application was terminated. Subsequently,
plasma concentrations decreased (Fig. 1).
The plasma concentration time course best fitted a two-
compartment model using a population approach with inter-
occasional variability (Table 1). No statistically significant
correlation between model parameters and age, weight,
height, BMI, LBM, and BSA was found. The influence of sex
was not evaluated.
A goodness-of-fit plot for the two-compartment model
shows that the Bayesian prediction for each volunteer
Nefopam 0.5 mg ml–1 : scheme A
0 200 400 600 800
N
ef
op
am
 p
la
sm
a
co
n
c.
 (n
g 
m
l–1
)
0
350
700 Nefopam 1.0 mg ml–1 : scheme A
0 200 400 600 800
0
350
700
Nefopam 0.5 mg ml–1 : scheme B
t (min) t (min)
t (min) t (min)
0 200 400 600 800
0
75
150 Nefopam 1.0 mg ml–1 : scheme B
0 200 400 600 800
0
75
150
N
ef
o
pa
m
 p
la
sm
a
 
co
n
c.
 
(ng
 m
l–1
)
Fig 1 The curves show the concentration–time relationship of i.v. administered nefopam according to scheme A (upper panels) and scheme B
(lower panels). Details of the infusion schemes are given in the Appendix. This is a raw data presentation of individualized treatment schemes
only. Thermal manipulations finished at different times due to pharmacodynamic defined points in the study (maximum intensity of shivering
during cooling with cold infusions). Therefore, the appearance of time and concentration once the concentration decrease begins varies.
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matched the observations (measured plasma concentra-
tions) well over the entire concentration range (Fig. 2). The
PK parameters of nefopam are shown in Table 2. The
central compartment V1 was 24.3 litre and clearly larger
than the blood volume undergoing a quick distribution
(t1/2a¼4.5 min) into an even larger compartment V2 with
183.3 litre being eliminated from plasma with a terminal
plasma elimination half-life of 5 h. IIV ranged from 15.7
(V2) to 39.1 (V1) %CV as given in Table 2. The IOV was esti-
mated to be between 7%CV (Clel) and 16%CV (V1).
Plotting the relative residuals of the population and
Bayesian prediction against time and concentrations,
respectively, showed that the model misspecifications were
well controlled, the Bayesian approach delivering more
accurate predictions (Fig. 3). The MDPE (10th; 90th percentile)
for the final model was 26.15 (225; +16)% and the MDAPE
was 16.63 (10; 29)%.
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Fig 2 Goodness-of-fit plot. Circles lying on the line of identity cor-
respond to optimal predictions (residual equals zero). Both the
population predictions and the Bayesian predictions are calcu-
lated with the parameters from Table 2.
Table 1 Objective function values. The model building process is
shown by displaying the numbers of the minimum objective
function value (OFV) for each model (I, II, III, one-, two-, or
three-compartment model) and the approach (NPD, naı¨ve pooled
data; POP, population approach). Models (B) and (C) specify that
data sets from two different occasions in the same subject were
used (individual¼non-pooled data) whereas model (A) does not
distinguish between occasions (pooled data) and treats every
data set as independent. IOV, inter-occasional variability. The
lower the number and less complex the model, the better
I II III
(A) Pooled data
NPD 4481 3352 3344
POP 4396 2858 2830
(B) Individual data
POP 4412 3045 3017
(C)¼(B) with IOV
POP 4399 2858 Unstable
Table 2 Pharmacokinetic parameters for nefopam. (A) NONMEM
parameterization implemented for calculations; (B) derived
parameters, therefore SE not applicable. IIV, inter-individual
variability (square roots of the variances of the ETAs, expressed as
percentage value); IOV, inter-occasional variability; CV, coefficient
of variation; Clel, plasma clearance; Cldist, distributional clearance
(Q); V1, V2, Vdss, volumes of distribution in the central or peripheral
compartment, or at steady-state, respectively; t1/2a,
intra-compartmental half-life time; t1/2b, plasma elimination
half-life time; k10, k12, k21, micro rate constants
Variable Unit Typical value (SE) IIV (CV%) IOV
(CV%)
A V1 Litre 24.1 (2.8) 39 16
V2 Litre 183.3 (13.5) 15 9
Clel Litre min
21 0.54 (0.07) 23 7
Cldist Litre min
21 2.84 (0.42) 31 12
B Vdss Litre 207.5
t1/2a Min 4.5
t1/2b Min 306.5
k10 Min
21 0.022
k12 Min
21 0.1177
k21 Min
21 0.0155
Time (min)
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Fig 3 Relative residuals are the ratios Cmeasured/Cpredicted. In (A),
the relative residuals are plotted over time, and (B) displays the
relative residuals over the predicted concentrations.
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The covariance step of the final model was passed
successfully. Sixty-nine runs with minimization terminated
and 525 runs with estimates near a boundary (of the elimin-
ation clearance) were skipped when calculating the boot-
strap results, leaving 1406 runs available for calculation of
the SE quantiles during the bootstrap. The values for each
variable were as follows {variable (unit), mean [(2.5 and
97.5% standard error) (2.5 and 97.5% confidence interval)]}:
V1 (litre), 24.0 [(18.86, 29.3) (19.4, 29.5)]; V2 (litre), 184.8
[(155.9, 210.1) (159.0, 213.0)]; Clel (litre min
21), 0.54 [(0.42,
0.67) (0.43, 0.67)]; and Cldist (litre min
21), 2.79 [(2.08, 3.6)
(2.11, 3.6)].
The 80%, 50%, and 20% context-sensitive decrement
times for the plasma concentration were 38, 248, and 660
min after steady-state concentrations were established.
Context-sensitive decrement times are displayed in Figure 4.
Discussion
This study determined a complete compartmental PK data
set of i.v. administered nefopam during mild hypothermia
and checked its reliable predictive value by bootstrap
analysis. Therefore, a mathematical model to describe
plasma concentrations of nefopam at a specific time point
is available, in this case, a two-compartment model. This
model could be used to establish and maintain a desired
plasma concentration manually or automated with the limi-
tation of the unavoidable variability underlying a TCI system.
With the area under the curve method, Aymard and col-
leagues28 calculated (log2)/b (b, elimination rate constant
of the terminal log-linear phase) and distinguished a
terminal plasma elimination half-life time of i.v. adminis-
tered nefopam of 5.1 h, which is in good agreement with
our result based on compartmental PK. Mather and collea-
gues29 calculated a value of 3.8 and 4.1 h, respectively. In
our study, an average of 31 arterial blood samples were
drawn per volunteer on each study day over the course of
10–13 h. Mather and colleagues reported a period of 24 h
and 19 samples. It remains unclear why the terminal
plasma elimination half-life time Mather and colleagues
found differ from Aymard and colleagues’ result, and
from ours.
Altered clearance of various medications, especially
paralytics, propofol, fentanyl, phenytoin, and verapamil,
have been described during hypothermia and decreased
the clearance.30 The elimination clearance [Clel (SE %)] was
52.9 (6%) litre h21 for healthy volunteers, 37.0 (21%) litre
h21 for patients with end-stage renal disease (ESRD) not
yet haemodialysed, 27.3 (13%) litre h21 for ESRD patients
on chronic haemodialysis,31 and 32.4 (13%) litre h21 in our
hypothermia study, resembling the reduced value of the
elimination clearance of patients with ESRD compared with
healthy volunteers. Our value fits the picture of decreased
elimination clearances during hypothermia for other drugs.
The volume of the central compartment and the volume of
distribution during steady state present with less volume
during hypothermia compared with normothermia
(Table 3). This could be explained with vasoconstriction,
since the central compartment largely reflects intravascular
volume. Nefopam needs to be distributed out of the central
compartment quickly, being denoted by a large distributional
clearance Cldist¼2.84 (0.42) litre min21.
Nefopam will be used for the purpose of inducing toler-
ance to mild hypothermia. The main methods of inducing
and maintaining mild hypothermia are i.v. application of
cold fluids, applying ice or chemical packs, wrapping in mat-
tresses or other special cooling gants, cold forced air, and
endovascular cooling. Often a combination is applied, priori-
tizing cold fluid application initially. One study used
30 ml kg21 lactated Ringer’s solution at 48C infused over
30 min via a peripheral i.v. access.32 The median temperature
decreased after the bolus was 1.68C. Another study used
ice-cold saline solution, cold packs, and mattresses.33 Core
cooling in our study resulted from infusion of an average of
3.0–3.5 litre cold lactated Ringer’s solution. The amount of
volume administered in our study is slightly greater than
the one based on the recommendation by the above-
mentioned studies [2.3 (0.3) litre calculated for our study
population] for induction of therapeutic hypothermia but
reflects a whole study cycle (induction+maintenance) and
0
0
250
500
750
500 1000 1500
Time (min) since infusion start
80% decrement
50% decrement
20% decrement
Ti
m
e 
(m
in)
 to
 ta
rge
t
fra
ct
io
n
Fig 4 The context-sensitive decrement times in plasma. After a
certain infusion time (x-axis), stopping the infusion would take
the time indicated on the y-axis to reach one of the decrement
portions. Once steady state is reached, the times for the 80%,
50%, and 20% decrements are 38, 248, and 660 min.
Table 3 Kinetic parameters during hypo- and normothermia. Clel,
plasma clearance; Cldist, distributional clearance (Q); V1, Vdss,
volume of distribution in the central compartment or at steady
state; N/A, not applicable, derived parameter
Variable Unit Typical value (SE %)
Hypothermia Normothermia31
V1 Litre 24.1 (12%) 264 (8%)
Vdss Litre 207.5 (N/A) 529 (8%)
Clel Litre h
21 32.4 (13%) 52.9 (6%)
Cldist Litre h
21 170.4 (15%) 35.2 (13%)
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deals with non-anaesthetized volunteers compared with
anaesthetized patients. Therefore, the gathered data and
derived kinetics mirror clinical handling of the targeted field
of nefopam use to a great extent. This is a potential
benefit because data obtained in normothermic patients
would need to be extrapolated to hypothermic conditions
that we already incorporated in the study.
On top of the thermal influence on the kinetic parameters,
slight differences in the mode of administration, sampling,
and calculating parameters need to be taken into account.
In the normothermic study, people received a single dose
of 20 mg only, administered over 30 min,31 whereas the
hypothermic study administered up to 64 mg continuously
over a period up to 3 h, covering loading and maintenance
as well. The normothermic study lacks a maintenance infu-
sion and did not reach a steady state. Therefore, values of
the normothermic study are more prone to calculation
errors, since kinetic parameters needed to be extrapolated
by the software rather than being based on measured con-
centrations during a real maintenance period.
Both thermal manipulations and volume application in our
study reflect current practice in clinical use of mild hypo-
thermia, one field of nefopam assignment. In detail: during
the period of mild hypothermia and shivering, the measured
nefopam plasma showed a peak in the concentration curves
(Fig. 1). It is unclear if this effect could be attributed to
periods of increased shivering activity. Before thermal manip-
ulations took place, a stable nefopam plasma concentration
was established; after terminating cooling and stopping the
nefopam maintenance infusion, a regular decrease in
the nefopam plasma concentration was observed (Fig. 1).
The determined value for the terminal plasma elimination
half-life time of nefopam found in our investigation is in
accordance with the one Aymard and colleagues28 found
with a different method and without thermal manipulations.
Nevertheless, the model we determined describes the values
during all phases, including thermal manipulations.
We used serial samples in each volunteer, administering
nefopam with two different concentrations (one concentra-
tion per occasion) on two different occasions. The
minimum objective function values of the model building
process are shown in Table 1. As expected, treating two
different infusion regimes in one volunteer as two inde-
pendent individuals delivers slightly better results. Neverthe-
less, the correct declaration of two different dosing regimes
in the same subject on different occasions was used for
the presented data and also distinguishing between a popu-
lation and a non-population approach. Furthermore, introdu-
cing IOV in the model further lowered the minimum value of
the objective function from 3045 to 2858 and proved essen-
tial to avoid biased population parameter estimates.34
During bootstrapping, 525 runs, equalling 26%, were
skipped with estimates near a boundary. In all cases, they
were estimates of the elimination clearance. From a statis-
tical point of view, the skipped runs could bias the result.
The mean of the remaining runs is close to 0, but the SD is
only about 0.6. This could lead to an underestimation of
the CIs. The value for the elimination clearance derived
during model building is in accordance with values of other
publications determining it with different methods. Further-
more, the standard errors in modelling during the covariance
step show comparable results with bootstrapping (values not
displayed). Since we found similar results to other groups for
the elimination clearance and results in modelling and boot-
strapping are comparable, we hold the compartment model
established for a valid tool. It is no secret that there has been
a big controversial discussion in the community for years, if
parameters reaching a boundary should be discarded from
the bootstrap distribution; not only we believe it is the best
way to do so. Values beyond the used range could cause
numerical problems leading to estimated values outside a
reasonable physiological range.
The initial peaks seen in Figure 1 resulted from partial
overdosing, since the necessary amount of drug to be
infused was derived by estimation from available data.
Now, with the determined compartmental data set, such
overdosing could be avoided. With the compartmental
data set, the initial loading could be calculated to saturate
the central compartment without causing an overshoot
(and possible side-effects), replenishing the amount of
drug being distributed to peripheral compartments, or
being eliminated. By implementing this compartmental
PK data set (Table 2) into infusion pumps, the process
could be automated. After choosing a desired nefopam
plasma concentration, the infusion pump will establish
and maintain this concentration relieving work load on
medical personnel.
In Figure 2, we plotted measured vs predicted plasma
concentrations [predictions based on individual doses and
typical parameter values (¼population predictions), indi-
vidual doses and individual parameter values (¼Bayesian
predictions)]. The Bayesian predictions match the observa-
tions well over the entire concentration range. The fact
that several measured concentrations .200 ng ml21
deviate profoundly from the population predictions and
that these data points were observed during the initial infu-
sion time becomes obvious when cross-checking Figure 2
with Figure 1. It is well known that compartment models
(assuming instantaneous mixing) are not adequate for this
initial phase. A second option to explain such a bias for
higher concentrations would be non-linearity in such a way
that the clearance is not constant over the complete
concentration range but limited, for example, by enzyme
capacity. Only during the initial phase, loading concentra-
tions .200 ng ml21 were measured. Furthermore, assessing
the inter-individual variability of parameters determining the
drug concentrations in this phase before steady state
(Table 2), both the central volume of distribution and the
distribution clearance display the largest IIV (CV 39% and
31%, respectively). After termination of the infusion, the
decrease in plasma concentrations is predominantly
related to the Clel, which displays only modest IIV (CV
23%). This fact is supported by the MDPE of 26.15%
showing a slight overestimation of the model compared
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with the measured values. Thus, we attribute the deviations
of the population predictions from the measured values at
concentrations .200 ng ml21 to the known effect that
compartment models are not completely adequate for the
initial phase.
Another limitation of the study is the small age range
(21–39 yr) of people participating in the study. Furthermore,
the effects (if any) of gender could not be analysed, only two
women participated. Thus, nefopam kinetics for children, the
elderly, and women remain to be investigated. Because the
spread of biometric parameters (age, weight, height, sex) in
the study population was insufficient, we cannot conclude
that nefopam dosing is independent of weight, although
this is the current situation in clinical use.
To achieve and maintain a nefopam plasma concentration
of 100 ng ml21, scheme B with a nefopam concentration of 1
mg ml21 could be used. That scheme incorporates a ramping
to minimize the risk of side-effects such as nausea and
vomiting or dizziness. Nevertheless, adjusting the infusion
rate every few minutes is uncomfortable and time-
consuming. Therefore, the use of a target-controlled
automated pump using the determined kinetic data set is
recommended. Furthermore, it allows us to establish
various plasma concentrations, as desired (with the vari-
ability underlying a TCI system).
In conclusion, this is the first compartmental pharmoki-
netics of nefopam during hypothermia. A two-compartment
model with IOV reliably characterizes nefopam kinetics and
enables predictions of nefopam plasma concentrations at
any time point and could be used to establish and maintain
nefopam plasma concentrations, even automated by infu-
sion pumps.
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Appendix
Each scheme was completed by a total of four volunteers. In
a randomized order, one cycle with a concentration of 0.5 mg
ml21 nefopam and the other cycle with a concentration of
1.0 mg ml21 nefopam were administered.
Scheme A
Time (min) Infusion rate (ml h21)
0 164
5 163
10 20.4
15 21.7
20 20.6
25 19.6
30 18.7
35 17.9
40 17.1
45 16.4
50 15.8
55 15.2
60 14.6
65 14.1
70 13.6
75 13.1
80 12.7
85 12.3
90 11.9
95 11.6
100 11.3
105 11.0
110 10.7
115 10.5
120 10.3
125 10.1
130 9.9
135 9.7
140 9.5
145 9.4
150 9.2
155 9.1
160 8.9
165 8.8
170 8.7
175 8.6
180 0.0
Scheme B
Time (min) Infusion rate (ml h21)
0 60
5 19
20 17
30 14
40 11.5
55 9.5
75 8
100 6.5
135 5.5
180 0
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